These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Aspirin-exacerbated respiratory disease and current treatment modalities. Sakalar EG; Muluk NB; Kar M; Cingi C Eur Arch Otorhinolaryngol; 2017 Mar; 274(3):1291-1300. PubMed ID: 27538737 [TBL] [Abstract][Full Text] [Related]
9. Aspirin exacerbated respiratory disease: Current topics and trends. Rodríguez-Jiménez JC; Moreno-Paz FJ; Terán LM; Guaní-Guerra E Respir Med; 2018 Feb; 135():62-75. PubMed ID: 29414455 [TBL] [Abstract][Full Text] [Related]
10. PGE suppresses excessive anti-IgE induced cysteinyl leucotrienes production in mast cells of patients with aspirin exacerbated respiratory disease. Wang XS; Wu AY; Leung PS; Lau HY Allergy; 2007 Jun; 62(6):620-7. PubMed ID: 17508965 [TBL] [Abstract][Full Text] [Related]
11. COX-2: Where are we in 2003? - Specific cyclooxygenase-2 inhibitors and aspirin-exacerbated respiratory disease. Crofford LJ Arthritis Res Ther; 2003; 5(1):25-7. PubMed ID: 12716444 [TBL] [Abstract][Full Text] [Related]
12. Genetic and Epigenetic Components of Aspirin-Exacerbated Respiratory Disease. Dahlin A; Weiss ST Immunol Allergy Clin North Am; 2016 Nov; 36(4):765-789. PubMed ID: 27712769 [TBL] [Abstract][Full Text] [Related]
13. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease. White AA; Stevenson DD; Simon RA Ann Allergy Asthma Immunol; 2005 Oct; 95(4):330-5. PubMed ID: 16279562 [TBL] [Abstract][Full Text] [Related]